---
title: "Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV."
description: "The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomize"
url: "https://www.clareohealth.com/clinical-trials/NCT06436274"
---

The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.

## Key Facts

**ID:** NCT06436274
**Status:** ACTIVE_NOT_RECRUITING
**Phase:** PHASE4
**Type:** INTERVENTIONAL
**Enrollment:** 778
**Sponsor:** Massachusetts General Hospital

## About This Study

This clinical trial is testing the effectiveness of the GARDASIL®9 HPV vaccine in preventing HPV infection among women living with HIV. It aims to see how well a single dose of this vaccine works compared to a meningococcal vaccine, which is used as a control.

## Detailed Description

The HOPE II Study is an individual-level, randomized trial of immediate or delayed vaccination with a single-dose of the nonavalent HPV vaccine. The primary outcome is single-dose HPV 16/18/31/33/45/52/58 vaccine efficacy (VE). The study will provide evidence on the efficacy of single-dose HPV 16/18/31/33/45/52/58 vaccination among women living with HIV. Participants will be randomized 1:1 into two different Groups. * Group 1: Will receive nonavalent HPV vaccine at Day 0 and meningococcal vaccine at Month 18 * Group 2: Will receive the meningococcal vaccine at Day 0 and nonavalent HPV at Month 18 The meningococcal vaccine was chosen as the control vaccination because meningococcal vaccination has no activity against HPV infection. Further, the meningococcal vaccine has the potential to be of benefit in a meningitis outbreak context and could be beneficial for young persons in a congregate setting such as tertiary institutions.

## Conditions

- Human Papilloma Virus
- Hiv

## Interventions

**BIOLOGICAL: GARDASIL®9**
GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

**BIOLOGICAL: Menveo®/Menactra®**
Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

## Eligibility

Inclusion Criteria: 1. Age 16 years and above on the day of signing the ICF 2. Living with HIV with confirmed test results or clinic records 3.

## Who Can Participate

**Minimum age:** 16

**Sex:** FEMALE

**Accepts healthy volunteers:** No

## Study Locations

- Botswana Harvard Health Partnership, Gaborone, Botswana
- Ministry of Health and Center for Family Health Research, Kigali, Kigali, Rwanda
- Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

## Contact Information

## Important Dates

**Study start:** October 14, 2024

**Completion date:** June 1, 2027

**Last updated:** January 12, 2026

## Collaborators

- University of Witwatersrand, South Africa
- Botswana Harvard Health Partnership
- Ministry of Health, Rwanda
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
- Karolinska Institutet

## Consider Discussing with Your Care Team

### Worth Discussing If

- You are a woman aged 16 or older living with HIV.
- You have previously received an HPV vaccine.
- You have been sexually active in the last six months.
- You are interested in ways to prevent HPV infection.

### Questions to Ask

- Am I eligible to participate in this trial based on my health history?
- How does the GARDASIL®9 vaccine compare to other HPV prevention methods?
- What are the potential side effects of the vaccines being tested?
- How often will I need to visit the study site during the trial?
- What happens if I experience side effects during the trial?
- Will participating in this trial affect my current HIV treatment?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06436274)
